Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.
Salmonella-IL2 plus FOLFIRINOX may be more effective than FOLFIRINOX alone in patients with stage IV pancreatic cancer, a phase 2 study suggests.
Combination treatment with MEDI1191 and durvalumab has demonstrated activity in a phase 1 trial of patients with advanced solid tumors.
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
The bispecific antibody AFM13 elicits responses in patients with relapsed/refractory peripheral T-cell lymphoma, a phase 2 study suggests.
Petosemtamab can produce durable responses in patients with advanced head and neck squamous cell carcinoma, a phase 1/2 study suggests.
Following genetic screening guidelines may cause clinicians to miss as many as 40% of patients with high-risk hereditary cancer syndromes, a study suggests.
REGN5459 appears safe and can produce durable responses in patients with relapsed or refractory multiple myeloma, a phase 1/2 study suggests.
Neoadjuvant vibostolimab plus pembrolizumab has shown antitumor activity in a phase 1/2 trial of patients with stage IIIB-D melanoma.
Adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study suggests.
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
Adding pegargiminase to standard frontline chemotherapy improves outcomes in patients with nonepithelioid pleural mesothelioma, a phase 2/3 study suggests.
Results from the AEGEAN trial suggest that adding perioperative durvalumab to neoadjuvant chemotherapy can improve outcomes in patients with resectable NSCLC.
In a phase 2 trial, pembrolizumab produced an overall response rate of 89% in patients with unresectable desmoplastic melanoma.
The investigational drug VT3989 appears safe and can produce responses in patients with refractory mesothelioma or sarcoma, a phase 1 study suggests.
Adding pembrolizumab to frontline chemotherapy improves overall survival in patients with advanced biliary tract cancer, a phase 3 trial suggests.
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.